lunes, 10 de agosto de 2020

NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH/NIAID Template Banner

NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19

ACTIV-2

NIAID is supporting a set of adaptive treatment studies for COVID-19, part of the ACTIV public-private partnership, which are designed to test a variety of therapeutics with speed and flexibility. ACTIV-2 will begin by testing a monoclonal antibody treatment in volunteers with mild and moderate cases of the disease, who do not require hospitalization. Additional investigational therapeutics may be tested later in this study.

Read More

No hay comentarios:

Publicar un comentario